Literature DB >> 24650289

Whom and how to screen for Wilson disease.

Peter Ferenci1.   

Abstract

Wilson disease is a genetic disorder of hepatic copper excretion leading to copper accumulation in various tissues. The disease expression is highly variable, ranging from totally asymptomatic subjects to patients with severe liver disease or movement disorders. Thus, it is difficult to define in which patient Wilson disease has to be considered as diagnosis. The suspicion should be high in patients presenting with extrapyramidal disorders or with liver diseases or of unknown origin. For diagnosis, in many patients a combination of tests reflecting disturbed copper metabolism may be needed. Not a single test is per se specific and, thus, a range of tests has to be applied (presence or absence of Kayser-Fleischer rings or neurologic symptoms, serum ceruloplasmin, liver copper content, urinary copper excretion, mutation analysis; rated -1 to 4 depending on the test) and clinical symptoms. A diagnostic sum score of ≥ 4 confirms the diagnosis.

Entities:  

Keywords:  Kayser–Fleischer rings; Wilson disease; ceruloplasmin; genetics; hepatic copper content

Mesh:

Substances:

Year:  2014        PMID: 24650289     DOI: 10.1586/17474124.2014.899898

Source DB:  PubMed          Journal:  Expert Rev Gastroenterol Hepatol        ISSN: 1747-4124            Impact factor:   3.869


  7 in total

Review 1.  Encephalopathy in Wilson disease: copper toxicity or liver failure?

Authors:  Peter Ferenci; Tomasz Litwin; Joanna Seniow; Anna Czlonkowska
Journal:  J Clin Exp Hepatol       Date:  2014-09-22

2.  Hepatobiliary Quiz (Answers)-14 (2015).

Authors:  Sahaj Rathi; Radha K Dhiman
Journal:  J Clin Exp Hepatol       Date:  2015-06-27

Review 3.  Population screening and diagnostic strategies in screening family members of Wilson's disease patients.

Authors:  Huamei Li; Ran Tao; Lifang Liu; Shiqiang Shang
Journal:  Ann Transl Med       Date:  2019-04

4.  Wilson's disease in an adult asymptomatic patient: a potential role for modifying factors of copper metabolism.

Authors:  Georgios Loudianos; Simona Incollu; Eva Mameli; Maria B Lepori
Journal:  Ann Gastroenterol       Date:  2016 Jan-Mar

5.  Wilson's disease in Lebanon and regional countries: Homozygosity and hepatic phenotype predominance.

Authors:  Kassem Barada; Aline El Haddad; Meghri Katerji; Mustapha Jomaa; Julnar Usta
Journal:  World J Gastroenterol       Date:  2017-09-28       Impact factor: 5.742

6.  The macrophage activation marker soluble CD163 is elevated and associated with liver disease phenotype in patients with Wilson's disease.

Authors:  Emilie Glavind; Daniel N Gotthardt; Jan Pfeiffenberger; Thomas Damgaard Sandahl; Teodora Bashlekova; Gro Linno Willemoe; Jane Preuss Hasselby; Karl Heinz Weiss; Holger Jon Møller; Hendrik Vilstrup; William M Lee; Michael L Schilsky; Peter Ott; Henning Grønbæk
Journal:  Orphanet J Rare Dis       Date:  2020-07-02       Impact factor: 4.123

7.  Familial screening of children with Wilson disease: Necessity of screening in previous generation and screening methods.

Authors:  Huamei Li; Lifang Liu; Yun Li; Shendi He; Yujie Liu; Jinhong Li; Ran Tao; Wei Li; Shiqiang Shang
Journal:  Medicine (Baltimore)       Date:  2018-07       Impact factor: 1.889

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.